10 results about "Interleukin Gene" patented technology

Genetically modified non-human animals comprising a humanized interleukin-15 (IL-15) gene. Cells, embryos, and non-human animals comprising a human IL-15 gene. Rodents that express humanized or human IL-15 protein.

Provided are an atopic dermatitis improving agent and the like including a glyceryl ascorbic acid acylated derivative having a specific molecular structure.

The present disclosure relates to a recombinant expression vector for secretion of interleukin-21 and an attenuated Salmonella strain transformed therewith, and provides: a recombinant expression vector comprising an flgM gene and an interleukin-21 gene; an attenuated Salmonella strain transformed therewith; and a pharmaceutical composition for cancer treatment, comprising the attenuated Salmonella strain.

The application discloses siRNA targeting interleukin-24 genes and application thereof in treatment of sepsis, and belongs to the technical field of biological medicine. The nucleotide sequence of the siRNA comprises a sense strand shown in SEQ ID NO. 1 and an antisense strand shown in SEQ ID NO. 2; the 5' end of the sense strand is modified by cholesterol, and the 3' end of the antisense strand is modified by methoxy. It is found through animal experiments that the siRNA can effectively inhibit excessive inflammatory response in a sepsis model and significantly improve the survival rate, thereby providing a brand-new candidate drug and a precise target for treatment of sepsis.

The present application relates to a DNA drug, a gene targeting delivery system and its application in the treatment of lower extremity peripheral arterial disease. Specifically, the present application relates to a microcrystalline nanocarbon targeted drug delivery system and a plasmid containing human interleukin-4 gene loaded thereon. The delivery system comprises a matrix microcrystalline nanocarbon, and folate, polyethyleneimine and polyethylene glycol modified on the surface thereof. The matrix microcrystalline nanocarbon has a size of 5-20 nanometers, a crystallinity of >80%, a rich mesoporous structure, a high specific surface area and good biocompatibility. The present application also provides a preparation method of the system, which comprises the steps of synthesizing a matrix by pulse modulation radio frequency plasma enhanced chemical vapor deposition, surface functionalization modification and plasmid loading. After injection into the lower extremity muscle, the system can actively target the macrophages in the ischemic site, realize long-term expression of the IL-4 gene at the lesion site. It can effectively promote stable, mature functional angiogenesis by inducing macrophages to polarize to the repair M2 phenotype and regulating the OSM / GSNOR / ENG signal axis, thereby improving limb ischemia. The present application has important application value in the field of gene therapy for ischemic diseases, especially peripheral arterial disease and severe limb ischemia.

Oral cavity wound healing occurs in an environment that sustains ongoing physical trauma and is rich in bacteria. Patients undergoing cleft palate repair have a high degree of wound healing complications, such as oronasal fistula (ONF) formation. Following hard palate injury, ONF was created that demonstrated little change in pro-regenerative monocytes LY6Clo monocytes; however, there were increased M2 macrophages observed. Delivery of FTY720 nanofiber scaffolds following hard palate injury prevented ONF formation, allowed complete wound healing and was associated with increased LY6Clo monocytes and pro-regenerative M2 macrophages. Evaluation of interleukin gene expression revealed reduction in pro-inflammatory IL1 and IL6 and increased expression of pro-regenerative IL10 with FTY720 nanofiber delivery. The ability of FTY720 scaffolds to increase LY6Clo monocytes, increase M2 macrophages and alter the interleukin expression during hard palate mucosal healing demonstrates the ability of a FTY720-based autotherapy to improve oral cavity wound healing.

Disclosed herein are modified live virus (MLV) avian influenza reassortment-impaired, non-transmissible, immunogenic, and protective vaccines comprising the modification or rearrangement of internal influenza virus gene segments, incorporation of the DRPAVIAN peptide marker into HA, or modification of NA to encode the chicken interleukin-18 gene. Disclosed are also methods of preparing such MLVs and methods of using such MLVs for the treatment or prevention of influenza in a vertebrate.

Disclosed herein are modified live virus (MLV) avian influenza reassortment-impaired, non-transmissible, immunogenic, and protective vaccines comprising the modification or rearrangement of internal influenza virus gene segments, incorporation of the DRPAVIAN peptide marker into HA, or modification of NA to encode the chicken interleukin-18 gene. Disclosed are also methods of preparing such MLVs and methods of using such MLVs for the treatment or prevention of influenza in a vertebrate.

Described are RNAi agents, compositions that include RNAi agents, and methods for dual inhibition of a Thymic Stromal Lymphopoietin (TSLP) and Interleukin 33 (IL33) gene. The TSLP-IL33 RNAi agents disclosed herein inhibit the expression of a TSLP and an IL33 gene. Pharmaceutical compositions that include one or more TSLP-IL33 RNAi agents, optionally with one or more additional therapeutics, are also described. Delivery of the described TSLP-IL33 RNAi agents to pulmonary cells, in vivo, provides for inhibition of TSLP and / or IL33 gene expression, which can provide a therapeutic benefit to subjects, including human subjects, for the treatment of various diseases including asthma or chronic obstructive pulmonary disease (COPD).

The invention provides a primer probe combination, a kit and a detection method for detecting double polymorphic sites of a human interleukin 1beta gene, and the primer probe combination comprises a first pair of primers capable of amplifying an IL-1beta gene sequence and a first pair of probes for detecting rs16944 polymorphic sites of the IL-1beta gene, the first pair of primers can amplify the sequence of the IL-1beta gene, the second pair of primers can amplify the sequence of the IL-1beta gene, the second pair of probes is used for detecting the rs1143634 polymorphic site of the IL-1beta gene, and the nucleotide sequences of the first pair of primers are shown as SEQ ID NO. 1 and SEQ ID NO. 2. The nucleotide sequences of the first pair of probes are as shown in SEQ ID NO. 3 and SEQ ID NO. 4; and the nucleotide sequences of the second pair of primers are as shown in SEQ ID NO. 5 and SEQ ID NO. 6. And the nucleotide sequences of the second pair of probes are as shown in SEQ ID NO. 7 and SEQ ID NO. 8. The detection of the IL-1beta gene double polymorphic sites (rs16944 and rs1143634) can be completed by one reaction system, the method has the advantages of simplicity and convenience in operation, high sensitivity, strong specificity, large detection flux, low cost and the like, and the detection result can be used for auxiliary diagnosis of various inflammatory diseases.